NasdaqGM:FATEBiotechs
Fate Therapeutics FY 2025 Loss Reduction Tests Bullish Narratives On Path To Profitability
Fate Therapeutics (FATE) closed out FY 2025 with Q4 revenue of US$1.4 million and a basic EPS loss of US$0.27, alongside a net loss of US$32.4 million. On a trailing 12 month basis, the company recorded revenue of US$6.6 million and a basic EPS loss of US$1.15 tied to a net loss of US$136.3 million. Over recent quarters, the business has seen quarterly revenue range between US$1.4 million and US$1.9 million and quarterly basic EPS losses move between US$0.27 and US$0.32. This keeps the focus...